NOW AVAILABLE FOR ORDERS ON/AFTER JULY 22ND We are refreshing our hereditary cancer test menu based on the latest medical management guidelines, clinical literature, and customer feedback to deliver the most up-to-date, clinically relevant testing options to healthcare providers and patients. Contact your regional Account Executive or Genomic …
Ovarian cancer can often appear quietly, with non-specific symptoms, making it difficult to detect at an early stage. Knowing if someone is at an increased risk for ovarian and other cancers can be critical for guiding early detection, prevention, or treatment. Genetic testing can help identify patients with hereditary cancer, allowing for personalized …
Ambry was founded with one goal– help patients and families. It is with this goal in mind that we design every test, accession every sample, interpret every result, and generate every report. Prior to becoming CEO at Ambry, I held various positions here, including Chief Scientific Officer for 5 years. Our motto is to design, validate and perform …
There are many factors that impact your patients’ risk to develop certain cancers, including whether or not they have a family history of the disease, which can significantly impact the likelihood they may develop cancers such as breast, colorectal, and prostate. Individuals with a strong family history of cancer may have a hereditary cancer …
At Ambry, we believe working together is better, that sharing data is essential to finding answers faster. Our scientists embody these beliefs by collaborating with other talented researchers and physicians to understand human disease, most recently in epilepsy genetics. We are proud to have contributed to the clinical research reviewed …
At Ambry, we offer many different options for genetic testing, sometimes more than one for the same disease, which we call “panels”. Ambry’s multi-gene testing panels are comprised of genes that have a threshold of evidence between a gene and the disorder for which a patient is being tested. These panels are made up of genes that are known …
Did you know that more than 1 in 4 of those with Lynch syndrome (LS) are missed by current genetic testing guidelines? New research from Ambry Genetics and Ohio State University of nearly 35,000 patients will change how the genetics community thinks about genetic testing strategies, lifetime cancer risks, and medical management for people with …
Hereditary diffuse gastric cancer (HDGC) is an inherited cancer syndrome caused by CDH1 gene mutations. It occurs most frequently in Japan and eastern Asia; current incidence in the U.S. is estimated at 10-40 individuals per 100,000.1 Individuals with mutations in the CDH1 gene have up to an 80% lifetime risk of diffuse gastric …
Advances in molecular diagnostics offer clinicians more choices than ever when it comes to disease-targeted genetic testing for their patients.1 However, the amount of options can complicate deciding which test is best for each patient. Next generation sequencing (NGS)-based clinical genetic tests, such as multi-gene panel testing (MGPT), offer …